Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Usage

1. Inspect the ampoule for particulate matter and confirm the suspension appears uniformly dispersed — shake gently if settled sediment is visible, as aqueous suspensions are expected to require resuspension.
2. Break the ampoule at the score line using a clean ampoule opener or gauze; draw the full 1 ml through a 21-gauge drawing needle to minimise particle fragmentation from the glass neck.
3. Switch to a fresh 23–25-gauge injection needle before administration — the drawing needle must never be used for injection, particularly critical with aqueous suspensions that can clog narrower gauges.
4. Select the intramuscular injection site — gluteus medius or lateral deltoid are optimal for aqueous suspensions, which distribute across muscle tissue rapidly but may sting transiently at injection.
5. Administer using slow, steady plunger pressure; rapid injection of aqueous suspension increases local discomfort due to the vehicle's lower viscosity compared to oil-based formulations.
6. Dispose of the opened ampoule and used needles in a designated sharps container immediately after injection; do not recap used needles and do not retain opened ampoules for subsequent doses.

Warnings

Frequently asked questions

How does stanozolol bind to the androgen receptor at a molecular level?

Stanozolol occupies the androgen receptor's ligand-binding domain through its A-ring pyrazole modification, which alters the three-dimensional fit compared with its parent compound dihydrotestosterone. This structural change reduces absolute binding affinity to roughly 35 % of DHT's, as catalogued in pharmacological receptor databases, yet delivers sustained anabolic gene activation because the compound resists enzymatic inactivation at the receptor site, prolonging occupancy relative to its binding constant.

Why is stanozolol classified as a DHT derivative and what does that mean for its effects?

Stanozolol is structurally derived from dihydrotestosterone, meaning it carries the fully saturated A-ring that characterises DHT but adds a pyrazole ring at positions 2 and 3. This lineage means stanozolol cannot be aromatised into oestrogen and cannot undergo further 5α-reduction, so its pharmacological activity is delivered exactly as administered. The result is a compound whose effects — nitrogen retention, SHBG reduction, erythropoietic signalling — occur without oestrogenic conversion as a competing variable.

How does stanozolol's androgen receptor affinity compare to nandrolone decanoate?

Stanozolol and nandrolone both bind the androgen receptor, but their receptor selectivity profiles diverge significantly. Nandrolone carries substantial progesterone receptor affinity — a pathway linked to progestogenic side effects — while stanozolol demonstrates negligible progesterone receptor activity. This means the two compounds produce anabolic signalling through partially overlapping but mechanistically distinct receptor interactions, making stanozolol the structurally cleaner AR-selective option of the two.

Why are single-dose 1 ml ampoules preferred over multi-dose vials for an aqueous stanozolol suspension?

Aqueous injectable suspensions carry a higher contamination risk per opening than oil-based solutions because water supports microbial growth more readily once the seal is breached. Single-dose 1 ml ampoules eliminate that risk entirely: each ampoule is opened once, used completely, and discarded. Stanobolin-50's 10×1 ml format means every injection is drawn from a freshly opened, LAL-tested sterile unit, eliminating cumulative contamination risk across a protocol.

Is 50 mg/ml considered a low, moderate or high concentration for injectable stanozolol, and does it affect injection frequency?

At 50 mg/ml, Stanobolin-50 is the entry-point concentration within injectable stanozolol product ranges — higher concentrations such as 100 mg/ml exist but require smaller injection volumes per dose, which some users find uncomfortable with aqueous suspensions. The 50 mg/ml concentration allows dose flexibility: a 50 mg dose equals exactly 1 ml (one ampoule), while a 25 mg dose requires only 0.5 ml, making precise titration straightforward without complex calculations or volume errors. (2) angle_used

Manufacturer

BM Pharmaceuticals' formulation development trajectory is most clearly illustrated by examining how Stanobolin-50 came to exist as an aqueous suspension rather than an oil-based solution — a distinction that reflects deliberate formulation chemistry decisions rather than default manufacturing convenience. Stanozolol is practically insoluble in fixed oils at pharmaceutical concentrations; oil-based formats would require solubilising excipients or concentration compromises. BM Pharmaceuticals' formulation team selected a sterile aqueous suspension vehicle matched to the API's solubility characteristics, applying micronisation parameters to the stanozolol particles to achieve consistent suspension stability and syringeability across the product's shelf life. This kind of API-specific formulation engineering — choosing the vehicle around the molecule rather than fitting the molecule into a standard vehicle — is a marker of the company's development philosophy. The 50 mg/ml concentration itself reflects a deliberate range decision: formulating below the 100 mg/ml threshold that aqueous stanozolol suspensions approach with difficulty, while maintaining sufficient concentration to deliver clinically meaningful doses in a 1 ml single-ampoule volume. Release specifications for each production batch require HPLC-confirmed potency within pharmacopoeial tolerance and LAL endotoxin values below the injectable-product threshold, with GMP documentation maintained to WHO guidelines throughout.